Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050262 | 0.86 | RAB9A (0.52) | RAB9APDE4BMAPTALDH1A1KDM4E | |
| SCHEMBL4047832 | 0.84 | CHRNA7 (0.61) | CHRNA7ALDH1A1KDM4E | |
| SCHEMBL4048359 | 0.83 | NQO2 (0.54) | RAB9APDE4BCHRNA7NPC1 | |
| SCHEMBL3451824 | 0.81 | RAB9A (0.50) | RAB9APDE4BMAPTALDH1A1KDM4E | |
| SCHEMBL4048361 | 0.76 | RAB9A (0.73) | RAB9APDE4BMAPTALDH1A1NPC1 | |
| SCHEMBL3326108 | 0.75 | CHRNA7 (0.51) | PDE4BCHRNA7MAPTALDH1A1KDM4E | |
| SCHEMBL4046578 | 0.75 | MMP13 (0.51) | RAB9AMAPTALDH1A1NPC1MAPK1 | |
| SCHEMBL4491225 | 0.72 | CHRNB2 (0.59) | CHRNA7MAPTALDH1A1KDM4E | |
| SCHEMBL5946808 | 0.72 | CHRNA7 (0.46) | RAB9APDE4BCHRNA7MAPTALDH1A1 | |
| SCHEMBL3451493 | 0.72 | RAB9A (0.71) | RAB9APDE4BMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | claimed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | claimed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | claimed |
| EP-1819709-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-22 | — | — | EP | claimed |
| WO-2006058879-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH A/S (DK) | 2006-06-08 | — | — | WO | claimed |
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | disclosed |
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | NEUROSEARCH A/S (DK) | 2007-11-15 | — | — | US | disclosed |
| EP-1819709-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058879-A1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH A/S (DK) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265271-A1 | Novel Diazabicyclic Aryl Derivatives as Cholinergy Ligands | CHRNA6, CHRNA10, CHRNA2 | RAB9A 2936/4885PDE4B 217/4885CHRNA7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.